TRAVERE THERAPEUTICS, INC. (TVTX) Operating cash flow 2016–2025
TRAVERE THERAPEUTICS, INC. (TVTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$37.8MFY2025 · since FY2016: -$3.4M → $37.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $37.8M | +115.9% |
| FY2024 | -$237.5M | +15.2% |
| FY2023 | -$280.0M | -50.3% |
| FY2022 | -$186.3M | -1159.4% |
| FY2021 | -$14.8M | +65.4% |
| FY2020 | -$42.7M | +26.6% |
| FY2019 | -$58.2M | -133.2% |
| FY2018 | -$25.0M | -437.1% |
| FY2017 | $7.4M | +315.1% |
| FY2016 | -$3.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Net marginTVTX Gross profitTVTX Gross marginTVTX Operating incomeTVTX Operating marginTVTX Free cash flowTVTX Capital expendituresTVTX Return on equityTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Total liabilitiesTVTX Shareholders’ equityTVTX overview →